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We have approached the problem on the basis of results obtained in experimental chemotherapy of Mycobacterium leprae infections in mice, 4 -12 observations made in man 13-15 and prospective chemotherapeutic trials in patients. 1 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] From studies in mice and man, we know that there are at present two bactericidal drugs: rifampicin (RMP) and the thioamides (either ethio-or prothionamide, ETH or PRO), and two mainly bacteriostatic drugs: dapsone (DDS) and clofazimine (CLO). RMP is extremely bactericidal, killing about 5 logs of M. leprae after a single dose of 1500 mg or a few doses of 600 mg. Due to its profound effect on M. leprae, it can also be given intermittently up to once a month8 whereas ETH or PRO when administered less than three times a week, are inactive.9, l o Dapsone and clofazimine are interchangeable as bacteriostatic drugs, and since they have a different action mechanism they do not show cross-resistance.
From what was known in the treatment of tuberculosis, we concluded that what was needed for the treatment ofMB leprosy was l ,2 an association of two and preferably three, bactericidal drugs (but only two are available in leprosy) in order to obtain maximal killing of M. leprae; and the addition of a bacteriostatic drug, whose main role would be to prevent the selection of organisms resistant to the bactericidal drugs.
In this interpretation of the events occurring during chemotherapy, the use of a second bacteriostatic drug was unnecessary. We therefore used in all our trials DDS in new patients and replaced it by CLO in patients at risk for secondary DDS-resistance, defined as those patients who had been treated with DDS for 5 0305-75 I 8/86/057265S +07 $0 1 .00 © British Leprosy Relief Association years or more. (The importance of primary DDS resistance was unknown when we started our studies.)
We accepted as an unproven premise, that daily administration ofRMP had a greater bactericidal effect than intermittent administration. Although we had fo und that, with the Morphological Index as a measure, there was no difference between daily 600 and weekly 900 mg of RMp16 and with relapse as a measure15 two doses of 600 mg RMP per week were sufficient. Thus it was clear that in the association ETH-RMP, the latter could be given intermittently but with what intervals remained to be investigated.
As a conservative measure the first regimens studied contained daily administration of the combination RMP-ETH. In later trials RMP was given intermittently after an introductory phase of daily RMP.
The question of the duration of therapy has many facets. A particular aspect to be fully realized in the treatment of leprosy, is the dissociation between bacterial killing and skin smear status: M. leprae can be rapidly killed by appropriate bactericidal drugs but the dead bacilli are extremely slowly eliminated by the host. This means that the Bacterial Index cannot be used as a measure of cure-only the eventual appearance of relapse is a reliable criterion.
Thus the question concerning the moment of appearance of relapses becomes crucial, since this will define the duration of the fo llow-up period after the end of treatment and will influence greatly the time scale for prospective treatment trials. Our observations showed that 50% of relapses in MB disease appear within 2 years and 50% of relapses in PB leprosy within 3 years after the end of therapy.2 0 .2 1 We thus proceeded on the premises that antibacterial treatment can be stopped in the presence of a positive BI, and that the measure for cure is the absence of relapse, being documented by congruent clinical, bacteriological (MI!) histopathological information, together with the result of mouse fo otpad inoculation of bacteria from a skin biopsy.
The duration of treatment can only be defined by trial and error. We decided to proceed stepwise downward fr om 1 year. This I-year period was not entirely arbitrary: in the treatment of tuberculosis, regimens comprising two bactericidals were highly effective when applied during 9-12 months.
The fo llowing 12 month regimens were tested in Burundi and on the island of Anjouan, Republic of the Comores1 7:
8--44 RED 8W RMP 600 7/7 +44 W RMP 600 1/7 52W ETH 500 7/7 52W DDS 100 7/7 8-44 REC 8W RMP 600 7/7 +44 W RMP 600 1/7 52W ETH 500 7/7 52W CLO 100 7/7
The REC regimen was given to patients at risk of or with proven secondary DDS resistance. 23 The results are presented in Table 1 . It may be concluded fr om these results that MB leprosy can be cured by a treatment regimen of I-year duration. However these regimens are difficult to apply on a large scale. It was therefore decided to start another trial in which the supervised treatment was reduced to 6 months. In Zaire and Rwanda the following regimens were applied:
ETH 500 7/7 or (randomization) CLO 100 7/7 +26W CLO 100 7/7 Regimen RED was administered to all newly diagnosed male patients and all male patients treated previously for less than 5 years. They were randomized between RED/ED and RED/D. Regimen REC was administered to all fe male patients and all male patients treated previously for 5 years or more. They were randomized between regimens RECfEC and RECfC.
The results are presented in Table 2 , and the confidence limits for the different groups and regimens in Table 3 .
The results of this study show that it is possible to cure MB leprosy by a Number of patients with 3 year fo llow-up/number of patients taken in. Upper 95% confidence limits for absence of relapses after 2 and 3 years. RED in new patients: 0/89 = 4·0% RED in new and old patients: 0/143 =2'50%. Overall 0/160=2'28% (+ 1 ), 1 pt not seen at 2 years, was so at 3 years treatment regimen of I-year duration, during which rifampicin is given during the first 6 months only. Since RMP is the main bactericidal, and since there is no difference between the administration of DDS or CLO with and without ETH during the second semester, it seems that ETH has little effect. The necessity of any additional treatment after 6 months of a powerful bactericidal combination may even be questioned. Therefore a regimen of 6 months duration was tested. Such a regimen was applied in Istanbul in collaboration with T. Saylan et al. 1 9 2W RMP 600 7/7 + 24W ETH 500 7/7 DDS 100 7/7
RMP 600 1/7 ETH 500 7/7 DDS 100 7/7 (With DDS replaced by CLO in patients treated for 5 years or more with DDS) .
Unfortunately only a small number of patients could be fo llowed for 2 years after the end of treatment, widening the confidence limit to 11·9%.
The above regimens were also accompanied by a serious and unforeseen complication, namely toxic hepatitis due to the association RMP-ETH. It occurs in 3·5-5% of patients, after 5-186 days of treatment, with a mean of93 days and a median of 76 days, whether the combination RMP-ETH is given daily throughout or only during an introductory phase of 2-8 weeks.
In the meantime results of a still shorter drug regimen of 3 months duration have become available. The regimen is:
13W RMP 600 2/7 ETH 500 7/7 DDS 100 7/7 (or CLO 100 7/7)
Sixty-four patients were taken into the trial. From each of them 5 . 103 bacilli fr om the skin were inoculated into mouse fo otpads in Antwerp to ascertain the viability of the organisms.
Bacilli from 33 patients proved infectious for mice. These patients were all bacteriologically positive at the end of therapy. Biopsies fr om patients have again been inoculated into mouse fo otpads at 2 years fo llow-up. No viable bacilli could be detected. The patients have been fo llowed for the third year, none of them has shown any sign of relapse. Furthermore, not a single case of hepatitis has been observed. This may be the result of several concurrent factors:
Considerable shortening of the duration of treatment: whereas toxic hepatitis manifests after a median treatment duration of 93 days, a 90-day regimen should eliminate 50% of hepatitis cases. 2 RMP is administered intermittently twice a week fr om the very start of treatment. 3 The small number of patients in this study (39). However a total of 61 were included, 22 of them with negative mouse fo otpad results, and not included in the final analysis of the results of the antibacterial treatment.
In conclusion MB leprosy can be cured by regimens of 12, 6 and even 3 months duration. Table 4 shows the confidence limits of the results obtained in relation to the number of doses of RMP administered and the duration of therapy. Daily administration of RMP is not a necessity thus invalidating one of our starting premises. Depending on the regimens, twice or even once weekly administrations are sufficient, thus improving also on the toxicity.
It seems that as in experimental chemotherapy in the mouse there is a relationship between the dosage of RMP, the intermittency and the duration of treatment, allowing for widely different regimens in terms of the total dose of RMP administered and the duration of treatment. Thus regimens could be devised that are adapted to widely different local situations.
